Drug Delivery (Jan 2017)

Marked augmentation of PLGA nanoparticle-induced metabolically beneficial impact of γ-oryzanol on fuel dyshomeostasis in genetically obese-diabetic ob/ob mice

  • Chisayo Kozuka,
  • Chigusa Shimizu-Okabe,
  • Chitoshi Takayama,
  • Kaku Nakano,
  • Hidetaka Morinaga,
  • Ayano Kinjo,
  • Kotaro Fukuda,
  • Asuka Kamei,
  • Akihito Yasuoka,
  • Takashi Kondo,
  • Keiko Abe,
  • Kensuke Egashira,
  • Hiroaki Masuzaki

DOI
https://doi.org/10.1080/10717544.2017.1279237
Journal volume & issue
Vol. 24, no. 1
pp. 558 – 568

Abstract

Read online

Our previous works demonstrated that brown rice-specific bioactive substance, γ-oryzanol acts as a chaperone, attenuates exaggerated endoplasmic reticulum (ER) stress in brain hypothalamus and pancreatic islets, thereby ameliorating metabolic derangement in high fat diet (HFD)-induced obese diabetic mice. However, extremely low absorption efficiency from intestine of γ-oryzanol is a tough obstacle for the clinical application. Therefore, in this study, to overcome extremely low bioavailability of γ-oryzanol with super-high lipophilicity, we encapsulated γ-oryzanol in polymer poly (DL-lactide-co-glycolide) (PLGA) nanoparticles (Nano-Orz), and evaluated its metabolically beneficial impact in genetically obese-diabetic ob/ob mice, the best-known severest diabetic model in mice. To our surprise, Nano-Orz markedly ameliorated fuel metabolism with an unexpected magnitude (∼1000-fold lower dose) compared with regular γ-oryzanol. Furthermore, such a conspicuous impact was achievable by its administration once every 2 weeks. Besides the excellent impact on dysfunction of hypothalamus and pancreatic islets, Nano-Orz markedly decreased ER stress and inflammation in liver and adipose tissue. Collectively, nanotechnology-based developments of functional foods oriented toward γ-oryzanol shed light on the novel approach for the treatment of a variety of metabolic diseases in humans.

Keywords